This study showed that the percentage of CD19+ total B cells, CD19+CD27+ memory B cells, and CD19−CD27+CD138+ plasma B cells, the levels of TNF-α, BAFF, laboratory parameters, and clinical indicators of RA patients all decreased after etanercept treatment. This evidence concerns the gene CD19 and rheumatoid arthritis.